Extended Drug Information

LIMITATIONS OF PROCEDURE

  • Only human oral fluid should be used.
  • Results on the LE5 Drug Tester are preliminary qualitative analytical test results. A positive response will require confirmation by a laboratory based reference assay.
  • The presumptive presence of drugs is not a measure of intoxication.
  • A negative result may not necessarily indicate a drug free sample. Drugs may be present below the stated cut off.
  • Foods/medicines or preclinical errors may result in false results.


DIRECTIONS FOR USE

Prior to use, the test device and cartridge should reach room temperature (+15 to +30°C).


PERFORMANCE CHARACTERISTICS

Independent Laboratory Testing

Test strips were evaluated by two independent laboratories.
Testing used fresh saliva with no drugs provided a ‘Negative’ saliva, and with fresh saliva spiked to give drug concentrations at +50% of the cut-off, ‘Positive’ saliva. The drug concentrations were verified using LC-MSMS.
Ten independent tests were made at each drug concentration.
The drugs evaluated were Methamphetamine, Cocaine, Amphetamine, Oxycodone, ∆9-THC and Morphine*.

NOTE: You may need to scroll the table below left/right for more information

DRUG

CUT-OFF ng/ml

% ACCURACY NEG saliva (n=10)

% ACCURACY +ive saliva (n=10)

Methamphetamine

50 ng/ml

100

100

Cocaine

50 ng/ml

100

100

Amphetamine

50 ng/ml

100

100

∆9-THC

15 ng/ml

100

100

Opiates

50 ng/ml

100

100

Oxycodone

40 ng/ml

100

100


SPECIFICITY

Druglizer LE5 results listed in the following table are based on our manufacturers statements provided. The specificity was evaluated by testing various drugs, their metabolites and other drugs present in oral fluid. All compounds are prepared in an artificial saliva. Positive results are obtained at concentrations greater than that listed.

NOTE: You may need to scroll the table below left/right for more information

DRUG TEST

TEST COMPOUNDS

CONCENTRATION (ng/ml)

Amphetamine (AMP50)

D-Amphetamine

50

-

L-Amphetamine

4,000

-

β-Phenylethylamine

25,000

-

Tryptamine

12,500

-

p-Hydroxyamphetamine

100

-

(+)-3,4Methylenediozyamphetamine (MDA)

100

-

Methoxyphenamine

12,500

Cocaine (COC50)

Benzoylecgonine

50

-

Cocaine

50

-

Cocaethylene

50

-

Ecgonine

3000

-

Ecognine methyl ester

25,000

Marijuana (THC25)

∆9-Tetrahydrocannabinol

25

-

∆8-Tetrahydrocannabinol

75

-

11-nor-∆9-THC-9 COOH

12

-

11-hydroxy-∆9-THC

300

Methamphetamine (MET50)

d-Methamphetamine

50

-

Fenfluramine

60,000

-

p-Hydroxymethamphetamine

400

-

L-Phenylephrine

6,250

-

MDEA

50

-

MDMA

50

-

Procaine

2,000

-

Methoxyphenamine

25,000

-

Mephentermine

1,500

-

Ephedrine

400

-

Benzphetamine

25,000

Opiates (OPI50)

Morphine

50

-

Codeine

30

-

Diacetylmorphine (Heroin)

75

-

Ethylmorphine

30

-

Hydrocodone

125

-

Hydromorphone

125

-

6-Monoacetylmorphine (6-MAM)

25

-

Morphine-3-ß-D-Glucoronide

75

-

Narlorphine

12,500

-

Oxycodone

31,250

-

Oxymorphone

31,250

-

Thebaine

2,500

-

Levorphanol

500

-

Norcodeine

9,000

-

Normorphine

31,250

-

Pholcodine

500

-

Methadone

1,000

-

Dolantin

1,000

Benzodiazepine (BZO10)

Clobazam

10

-

Clonazepam

25

-

Delorazepam

50

-

Alprazolam

10

-

Hydroxyalprazolam

100

-

Bromazepam

50

-

Chlordiazepoxide

50

-

Clorazepate

25

-

Diazepam

100

-

Estazolam

400

-

Desalkylflurazepam

10

-

Flunitrazepam

10

-

Lorazepam

200

-

Nordiazepam

50

-

Midazolam

400

-

Norchlordiazepoxide

10

-

Oxazepam

10

-

Temazepam

10

-

Tranxene

25

-

Triazolam

200

Oxycodone (OXY40)

Oxycodone

40

-

Oxymorphone

80

-

Levorphanol

10,000

-

Hydrocodone

1,500

-

Hydromorphone

10,000

-

Naloxone

5,000

-

Naltrexone

5,000

*Methamphetamine, Cocaine, Amphetamine, Opiates and Oxycodone have shown by independent laboratory to be compliant with AS/NZS 4706:2019

BIBLIOGRAPHY

  1. Oral Fluid Testing for Drugs of Abuse. Bosker W.M. Huestis M.A – Clin.Chem 55:11 1910-1931 2009.
  2. Drug Testing in oral fluid evaluation of sample collection devices.
    Langel K, Engblom C, Pehrsson A, Gunner T, Ariniemi K, Lillsunde P. – j.Anal Toxicol. 2008;32: 393-401.
  3. Current knowledge on cannabinoids in oral fluid. Lee D, Huestis M.A – Drug Test Analysis 2014, 6, 88-111.
  4. Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology and treatment literature. Courtney K.E Ray L.A – Drug Alcohol Depend. 2014, Oct 1; 143: 11-21.